Abstract 537P
Background
Pulmonary metastasectomy is a commonly performed operation, but with inconclusive evidence for effectiveness. The aim of this study is to investigate the patient outcome after pulmonary metastasectomy in sarcoma patients with pulmonary metastases.
Methods
We retrospectively reviewed patients undergoing pulmonary metastasectomy for metastatic soft tissue and bone sarcomas in a single center. Treatment-free interval (TFI) was defined as the duration from the last date of primary tumor treatment to pulmonary metastasectomy. Recurrence-free interval (RFI), defined as the time from pulmonary metastasectomy to identification of new pulmonary metastasis, was calculated to determine freedom from lung recurrence. Post-metastasectomy survival (PMS) was defined as the time from pulmonary metastasectomy to death. Kaplan-Meier plots and Log-rank test were used to identify prognostic factors.
Results
Data of 102 patients were include in the analysis. In the RFI analysis, 77.4% patients (79/102) developed new pulmonary metastasis after pulmonary metastasectomy, with a median duration of 8.9 months. The 2-year freedom from lung recurrence was 23.6% and 51.9% in patients with TFI less than 12 months and TFI more than 12 months, respectively (p = 0.040). In the PMS analysis, the extrathoracic recurrence (p = 0.004) and TFI, but not primary site tumor recurrence, were significant prognostic factors. The 2 and 5-year PMS rates were 68.5% and 38.1%, respectively, in patients in patients with TFI less than 12 months, compared to 80.3% and 67.6%, respectively, in patients with TFI more than 12 months (p = 0.028).
Conclusions
A significant proportion (77.4%) of patients developed lung recurrences after pulmonary metastasectomy for sarcoma. Patients with TFI more than 12 months were associated with higher rate of freedom from lung recurrence and better PMS after pulmonary metastasectomy for sarcoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract